Checkpoint (receptor:ligand) | Disease | Functional change | PMID# | Year |
---|---|---|---|---|
Forward immune checkpoint (towards TC) | ||||
 CD40:CD40L | ACS | Lesion CD40L+ TC↑ | 12732389 | 2003 |
Bladder tumor | Peripheral T cell↓ to agonistic IgG1 chimeric α-CD40 Ab | 25589626 | 2015 | |
 CD137:CD137L | AS | CD137↑ in lesion CD8+ TC | 18285570 | 2008 |
Head/neck cancer | CD4+/CD8+ TC proliferation maker Ki67↑ to CD137 agonist | 27496866 | 2016 | |
 CD134:CD134L | ACS | CD134+ CD4+CD28null TC express INF-γ/TNF-α, | 22282196 | 2012 |
Colorectal cancer | CD134+ CD8+ TC infiltration enhances prognostic | 26439988 | 2015 | |
 CD27:CD70 | NSCLC | Higher CD4/CD8 TC ratio in CD70+ tumor cell | 25951351 | 2015 |
 CD30:CD30L | Lymphoma | CD30+ Th2 proliferation↓ by CD30L | 12855655 | 2003 |
 GITR:GITRL | Liver tumor | Tumor-infiltrating Treg-suppressive capacity↓ by GITRL | 26587321 | 2015 |
Reverse-immune checkpoint (towards APC) | ||||
 CD40:CD40L | CVD + CKD | CD40+ MC↑, MC inflammatory markers↑ | 27992630 | 2016 |
Cancer | CD40L mediate TIS-TC induced inflammatory MC/MØ | 25375372 | 2014 | |
 CD137:CD137L | AAS | CD137L+ CD14+ MC↑ | 24899613 | 2014 |
MM | CD137 inhibit MM cell proliferation and induce death | 20520765 | 2010 | |
 CD134:CD134L | ACS | OX40L+ MC↑ | 22282196 | 2012 |
MLC | OX40L+ MLC-DC express higher CD80+/CD86+/HLA-DR | 14984494 | 2004 | |
 CD27:CD70 | Lymphoma | Anti-CD70 mediate MØ phagocytosis | 17038522 | 2007 |
 CD30:CD30L | Lymphoma | Anti-CD30 mediate MØ phagocytosis | 17909075 | 2007 |
 GITR:GITRL | AS | Plaque MØ activation↑ | 17067317 | 2006 |